Arcturus Therapeutics Holdings Inc

ARCTNASDAQ · USD
8.31USD0.00 (-0.60%)
457

Arcturus Therapeutics Holdings Inc (ARCT) Covered Calls

Arcturus Therapeutics Holdings Inc trades in the Biotechnology industry with an IV Rank of 93.25%, high versus the past year. ARCT's highest covered call setup is the $30.00 strike expiring Mar 19, 2027, sorted by theoretical annualized return. It's 258.85% out of the money with 126 days to expiration, a 260.65% return until expiration, and a 755.05% theoretical annualized return. Across the setups shown, annualized returns run from 116.02% to 755.05% at strikes between $9.00 and $30.00, with 35 to 216 days to expiration, as of Nov 13, 2026.

Read more

Running ARCT covered calls helps you generate income from Arcturus Therapeutics Holdings Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ARCT covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If ARCT stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ARCT covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ARCT covered call is worth writing.

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc.

2027-03-1912630.00258.850.150.302179.00260.65755.05-1.79+0.10450.15
2027-03-1912625.00199.040.202.001684.00201.44583.52-2.39+0.31281.80
2026-12-183512.5049.520.050.60419.0050.12522.68-0.60+0.21960.55
2027-03-1912620.00139.230.052.801169.00139.83405.07-0.60+0.38942.75
2027-03-1912615.0079.430.402.05704.0084.21243.94-4.78+0.383311.65
2027-06-1721620.00139.230.051.051169.00139.83236.29-0.60+0.2221.00
2027-06-1721617.00103.350.054.90869.00103.95175.65-0.60+0.5304.85
2027-03-1912612.5049.520.601.75474.0056.70164.25-7.18+0.41991.15
2026-12-18359.007.660.551.20119.0014.23148.44-6.58+0.4800.65
2027-06-1721614.0067.460.102.85574.0068.66116.02-1.20+0.4302.75

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank93.25% High
  • Market cap (M$)240
  • 52 weeks high-53.73%
  • 52 weeks low51.09%
  • Analyst recommendationStrong Buy
    1.31
  • Target price$23.70
    185.20% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-05
  • P/E—
  • Future P/E—
  • EPS (ttm)-3.08
  • EPS growth next 5 years-11.55%

As of Nov 16, 2026